News and Trends 14 Dec 2022 OncoHost to launch PROphet for non-small cell lung cancer in the U.S. in 2023 Ofer Sharon is the CEO of OncoHost, a biotech company in the precision oncology space. A physician by training, Sharon has leveraged his experience in pharma drug development and entrepreneurship… December 14, 2022 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jan 2023 First leukemia patient dosed with SMART101 …related adverse events have been reported. Frédéric Lehmann, chief medical officer of Smart Immune, said: “The infusion of the first patient is a significant milestone in our journey to address… January 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 12 Feb 2018 MorphoSys’ CEO Tells Us What’s Next for Europe’s Antibody Expert …biotech scene – and it has grown to boast over 300 employees and a market cap of €2.2B, making it the largest public biotech in Germany. Its 25th birthday culminated… February 12, 2018 - 8 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Startup Scout 18 May 2018 This French Biotech Targets Retinal Cells to Treat Blindness Today, we’re in Paris, visiting SparingVision, a biotech trying to combat blindness using a protein that slows down the degeneration of cone cells in the retina. Mission: SparingVision uses a… May 18, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 5 Apr 2021 Base Editing: The Next Frontier in Genome Editing Technology …to ten gene-editing events to generate a persistent primary cell capable of surviving in an immunosuppressive tumor microenvironment. Although CRISPR, ZFNs, or TALENs can achieve this number of gene knockouts,… April 5, 2021 - 4 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Austrian Researchers Identify Target for Treatment of Multiple Sclerosis …different genes is regulated by the epigenome – chemical modifications that tell the genome how to behave. HDACs help to tightly package DNA, which prevents proteins from accessing the genome… October 19, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2024 CAR-T drugs and parkinsonism: a cause for concern? …is owned by pharma giant Johnson & Johnson and multinational biopharma Legend Biotech, and was greenlit for multiple myeloma in 2022. In the phase 3 trial that led to Carvykti’s… August 14, 2024 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2018 Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal …into a collaboration to advance their use in cancer immunotherapy. In a phase II trial, the company’s lead antibody, efgartigimod, reduced the number of bleeding events in patients with the… December 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Inside Labiotech 11 Jan 2018 A Day In The Life of a Labiotech-er …your favorite Labiotech team. 8:00 am: Evelyn, our Editor-in-Chief arrives. Why so early? Because she’s crazy. Also because the early bird gets the worm. Minions at work 9-9:30 am: The… January 11, 2018 - 4 minutesmins - By Katherine Douglas Share WhatsApp Twitter Linkedin Email
In Depth 1 Sep 2025 Blood Cancer Awareness Month: What biotech holds in store …the type of cancer that receives the most attention during the year, biotech is making progress, and companies are advancing very promising therapies through their pipelines. Hematologic malignancies pose unique… September 1, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type …a partial hold on the development of durvalumab in combination with tremelimumab after a number of ‘bleeding events’ unrelated to head and neck cancer were reported. As Endpoints reports, “AstraZeneca… October 28, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 30 Apr 2019 Orchard’s Gene Therapy Shows Potential in Treating Patients with Beta Thalassemia …the patient. The London-based biotech Orchard Therapeutics is developing a gene therapy that could provide a better alternative to current treatments. Acquired from GSK last year, this therapy involves taking… April 30, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email